Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT07325240

24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients

Led by Mayo Clinic · Updated on 2026-05-01

30

Participants Needed

1

Research Sites

97 weeks

Total Duration

On this page

Sponsors

M

Mayo Clinic

Lead Sponsor

A

Alcon Research

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the effect on 24-hour IOP reduction of netarsudil-latanoprost fixed combination in one eye compared to latanoprost alone in the contralateral eye, dosed daily, 1 drop at night (QD, PM) in adult subjects, at least 18 years of age, with open angle glaucoma (OAG) or ocular hypertension (OHT).

CONDITIONS

Official Title

24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of ocular hypertension or mild-to-moderate open angle glaucoma in both eyes (or OAG in one eye and OHT in the other) based on visual field, OCT, and dilated exam within one year
  • Intraocular pressure between 18 and 34 mmHg in both eyes on history or at screening
  • Able and willing to provide informed consent and follow study instructions
  • Able to cooperate with required exams and attend all study visits
  • Contact lens wearers willing to remove lenses at least 24 hours before study visits
  • Best-corrected visual acuity of +0.4 logMAR units (about 20/50) or better in each eye
Not Eligible

You will not qualify if you...

  • Narrow angles (3 quadrants with Grade 2 or less), angle closure, history of angle closure, or peripheral iridotomy in either eye
  • Severe glaucomatous damage
  • Difference in intraocular pressure between eyes greater than 4 mmHg unmedicated at any baseline time point
  • Use of more than two ocular hypotensive medications within 30 days of screening
  • Chronic or recurrent inflammatory eye diseases
  • Ocular infection or inflammation within past 3 months
  • Ocular trauma other than corneal abrasion within past 6 months
  • Significant retinal diseases like severe diabetic retinopathy or macular degeneration
  • Corneal changes preventing reliable measurements
  • Myopia greater than -6.00D or hyperopia greater than +2.00D
  • Central corneal thickness less than 480 µm or greater than 620 µm
  • Previous intraocular surgery except routine cataract surgery
  • Previous glaucoma surgery or laser procedures except SLT over 6 months ago
  • Unilateral intraocular surgery or laser procedures
  • Previous corneal refractive surgery
  • Severe dry eye
  • Use of ocular medications within 30 days before screening except IOP-lowering meds (must be washed out) and lubricating drops
  • Known allergy to study medication components
  • Significant systemic diseases interfering with the study
  • Participation in another interventional study within 30 days
  • Recent changes in systemic medications affecting eye pressure
  • Women of childbearing potential who are pregnant, nursing, planning pregnancy, or not using birth control
  • Known hypersensitivity or contraindications to study medications ingredients

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

Loading map...

Research Team

B

Bridgette Halder

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here